UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported):
October 23, 2003
ANTIGENICS INC.
(Exact name of registrant as specified in its charter)
DELAWARE 000-29089 06-1562417
(State or other jurisdiction of (Commission file number) (I.R.S. Employer
incorporation of organization) Identification No.)
630 FIFTH AVENUE, SUITE 2100
NEW YORK, NEW YORK 10111
(Address of principal executive offices and zip code)
(212) 994-8200
(Registrant's telephone number, including area code)
Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits.
(c) Exhibits:
99.1 Press Release dated October 23, 2003
Item 9. Regulation FD Disclosure (Information furnished pursuant to Item 12,
"Disclosure of Results of Operations and Financial Condition").
On October 23, 2003, Antigenics Inc. announced its financial results
for the quarter ended September 30, 2003. The full text of the press
release issued in connection with the announcement is attached as
Exhibit 99.1 to this current report on Form 8-K.
The information in this report on Form 8-K and the Exhibit attached
hereto is being furnished pursuant to Item 12 of Form 8-K, Disclosure
of Results of Operations and Financial Condition, and is presented
under Item 9, Regulation FD Disclosure, in accordance with the
procedural guidance in SEC Release No. 33-8216. The information shall
not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the
Exchange Act, except as expressly set forth by specific reference in
such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ANTIGENICS INC.
Date: October 23, 2003 By:/s/ Garo H. Armen
-----------------
/s/ Garo H. Armen
Garo H. Armen, Ph.D.
Chairman and Chief Executive Officer
EXHIBIT INDEX
The following designated exhibits are filed herewith:
Exhibits:
99.1 Press Release dated October 23, 2003